Calamos Advisors LLC purchased a new position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 305,303 shares of the biotechnology company’s stock, valued at approximately $12,945,000. Calamos Advisors LLC owned 0.17% of Cerevel […]
Avidity Partners Management LP raised its holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) by 28.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 643,000 shares of the biotechnology company’s stock after purchasing an additional 141,800 shares during the quarter. […]
Cerevel Therapeutics (NASDAQ:CERE – Free Report) had its price objective upped by Mizuho from $25.00 to $45.00 in a report issued on Friday morning, Benzinga reports. Mizuho currently has a neutral rating on the biotechnology company’s stock. A number of other equities analysts also recently commented on the company. Jefferies Financial Group reiterated a hold […]
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) shares saw an uptick in trading volume on Tuesday . 1,343,879 shares were traded during trading, a decline of 20% from the previous session’s volume of 1,682,243 shares.The stock last traded at $41.20 and had previously closed at $42.57. Analyst Upgrades and Downgrades A number of […]
Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) saw strong trading volume on Tuesday . 1,343,879 shares were traded during trading, a decline of 20% from the previous session’s volume of 1,682,243 shares.The stock last traded at $41.20 and had previously closed at $42.57. Wall Street Analysts Forecast Growth A number of […]